(Q82709945)
Statements
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer (English)
Manuel Philco
Patricia Pimentel
Miriam Kiyan
Maria Laura Monsalvo
Maureen G Conlan
Khalil G Saikali
Michael M Chen
Joseph J Seroogy
Andrew A Wolff
Rafael D Escandon